Patients with advanced NMSC show nuanced responses to immunotherapy

Melbourne researchers have described a delayed response after confirmed progression (DR) in patients with cutaneous squamous cell carcinoma (cSCC) treated with immune checkpoint inhibitors (ICIs). The researchers, from the Peter MacCallum Cancer Centre, reported three cases with unconfirmed disease progression after treatment of lesions with either cemiplimab or pembrolizumab. Signs included increased size of lesion, ...

Already a member?

Login to keep reading.

© 2021 the limbic